Drug Type: Unknown
Mechanism Type: Glutamate Excitotoxicity Blocker
Mechanism: GDC-0134 is an inhibitor of the dual leucine zipper kinase (DLK). It aims to promote survival of motor neurons in ALS by reducing glutamate-mediated excitotoxicity.
U.S. Status for ALS: Phase I
 Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease. Le Pichon, CE et al. Sci Transl Med. 2017 Aug 16;9(403). pii: eaag0394.
 Dual leucine zipper kinase is required for excitotoxicity-induced neuronal degeneration. Pozniak, CD et al. J Exp Med. 2013 Nov 18;210(12):2553-67.
 A Single-Ascending-Dose Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Patients With Amyotrophic Lateral Sclerosis. ClinicalTrials.gov, 1 Feb 2016. Accessed 11 Mar 2016 from https://clinicaltrials.gov/ct2/show/NCT02655614.
Last updated February 8th, 2018